{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:05:17Z","timestamp":1785870317507,"version":"3.56.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Projekt DEAL"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Osteonecrosis (ON) is an acquired debilitating skeletal disorder, which is caused by a multitude of traumatic and non-traumatic etiological factors. Vascular damage, mechanical stress and increased intraosseous pressure have been discussed as contributors to ON. The optimal treatment of ON remains to be determined, since the current gold standard, core decompression, is insufficiently effective. Specific properties of mesenchymal stromal cells (MSCs) provide the rationale for their assessment in advanced stages of ON: Osteoinductive potential has been demonstrated and MSC preparations of suitable quality for use as medicinal products have been developed. Here we review the scant information on the use of allogeneic or autologous MSCs in advanced ON as well as potentially supportive data from pre-clinical studies with autologous bone marrow mononuclear cells (auto BM-MNCs), which have been studied quite extensively and the presumed therapeutic effect of which was attributed to the rare MSCs contained in these cell products. Outcomes in clinical trials with MSCs and auto-BM-MNCs remain preliminary and non-definitive, at best promising, with respect to their pharmacological effect. Clearly, though, the application of any of these cell therapies was technically feasible and safe in that it was associated with low complication rates. The heterogeneity of cell type and source, study protocols, cell manufacturing, cell properties, cell doses and surgical techniques might contribute to inconsistent results.<\/jats:p>","DOI":"10.1186\/s12967-020-02565-9","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T12:03:58Z","timestamp":1603195438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Mesenchymal stromal cells for osteonecrosis"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9118-1163","authenticated-orcid":false,"given":"S.","family":"Elgaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Bonig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,20]]},"reference":[{"issue":"1","key":"2565_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4055\/cios.2016.8.1.1","volume":"8","author":"P Hernigou","year":"2016","unstructured":"Hernigou P, Trousselier M, Roubineau F, Bouthors C, Chevallier N, Rouard H, et al. Stem cell therapy for the treatment of hip osteonecrosis: a 30-year review of progress. Clin Orthop Surg. 2016;8(1):1\u20138.","journal-title":"Clin Orthop Surg"},{"issue":"1","key":"2565_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/scrt98","volume":"3","author":"L Rackwitz","year":"2012","unstructured":"Rackwitz L, Eden L, Reppenhagen S, Reichert JC, Jakob F, Walles H, et al. Stem cell- and growth factor-based regenerative therapies for avascular necrosis of the femoral head. Stem Cell Res Ther. 2012;3(1):7.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"2565_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1089\/ten.teb.2014.0090","volume":"20","author":"T Aoyama","year":"2014","unstructured":"Aoyama T, Goto K, Kakinoki R, Ikeguchi R, Ueda M, Kasai Y, et al. An exploratory clinical trial for idiopathic osteonecrosis of femoral head by cultured autologous multipotent mesenchymal stromal cells augmented with vascularized bone grafts. Tissue Eng Part B Rev. 2014;20(4):233\u201342.","journal-title":"Tissue Eng Part B Rev"},{"issue":"3","key":"2565_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s12178-015-9277-8","volume":"8","author":"KN Shah","year":"2015","unstructured":"Shah KN, Racine J, Jones LC, Aaron RK. Pathophysiology and risk factors for osteonecrosis. Curr Rev Musculoskelet Med. 2015;8(3):201\u20139.","journal-title":"Curr Rev Musculoskelet Med"},{"issue":"5","key":"2565_CR5","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1182\/blood-2007-02-070342","volume":"111","author":"NL Seibel","year":"2008","unstructured":"Seibel NL, Steinherz PG, Sather HN, Nachman JB, Delaat C, Ettinger LJ, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group. Blood. 2008;111(5):2548\u201355.","journal-title":"Blood"},{"issue":"18","key":"2565_CR6","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1200\/JCO.2007.14.9088","volume":"26","author":"NS Kadan-Lottick","year":"2008","unstructured":"Kadan-Lottick NS, Dinu I, Wasilewski-Masker K, Kaste S, Meacham LR, Mahajan A, et al. Osteonecrosis in adult survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2008;26(18):3038\u201345.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2565_CR7","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1182\/blood-2010-10-311969","volume":"117","author":"JD Kawedia","year":"2011","unstructured":"Kawedia JD, Kaste SC, Pei D, Panetta JC, Cai X, Cheng C, et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood. 2011;117(8):2340\u20137 (quiz 556).","journal-title":"Blood."},{"issue":"18","key":"2565_CR8","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1200\/JCO.2000.18.18.3262","volume":"18","author":"LA Mattano Jr","year":"2000","unstructured":"Mattano LA Jr, Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children\u2019s Cancer Group. J Clin Oncol. 2000;18(18):3262\u201372.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2565_CR9","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.3324\/haematol.12956","volume":"93","author":"ML te Winkel","year":"2008","unstructured":"te Winkel ML, Appel IM, Pieters R, van den Heuvel-Eibrink MM. Impaired dexamethasone-related increase of anticoagulants is associated with the development of osteonecrosis in childhood acute lymphoblastic leukemia. Haematologica. 2008;93(10):1570\u20134.","journal-title":"Haematologica"},{"issue":"11","key":"2565_CR10","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3324\/haematol.2016.147595","volume":"101","author":"M Kunstreich","year":"2016","unstructured":"Kunstreich M, Kummer S, Laws HJ, Borkhardt A, Kuhlen M. Osteonecrosis in children with acute lymphoblastic leukemia. Haematologica. 2016;101(11):1295\u2013305.","journal-title":"Haematologica"},{"issue":"14","key":"2565_CR11","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1182\/bloodadvances.2017007286","volume":"1","author":"M Kuhlen","year":"2017","unstructured":"Kuhlen M, Kunstreich M, Krull K, Meisel R, Borkhardt A. Osteonecrosis in children and adolescents with acute lymphoblastic leukemia: a therapeutic challenge. Blood Adv. 2017;1(14):981\u201394.","journal-title":"Blood Adv"},{"issue":"2","key":"2565_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.6061\/clinics\/2016(02)10","volume":"71","author":"HF Yuan","year":"2016","unstructured":"Yuan HF, Zhang J, Guo CA, Yan ZQ. Clinical outcomes of osteonecrosis of the femoral head after autologous bone marrow stem cell implantation: a meta-analysis of seven case-control studies. Clinics (Sao Paulo). 2016;71(2):110\u20133.","journal-title":"Clinics (Sao Paulo)"},{"issue":"6","key":"2565_CR13","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2106\/00004623-200406000-00006","volume":"86","author":"V Gangji","year":"2004","unstructured":"Gangji V, Hauzeur JP, Matos C, De Maertelaer V, Toungouz M, Lambermont M. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. A pilot study. J Bone Joint Surg Am. 2004;86(6):1153\u201360.","journal-title":"J Bone Joint Surg Am."},{"issue":"11","key":"2565_CR14","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1038\/leu.2008.217","volume":"22","author":"I Muller","year":"2008","unstructured":"Muller I, Vaegler M, Holzwarth C, Tzaribatchev N, Pfister SM, Schutt B, et al. Secretion of angiogenic proteins by human multipotent mesenchymal stromal cells and their clinical potential in the treatment of avascular osteonecrosis. Leukemia. 2008;22(11):2054\u201361.","journal-title":"Leukemia"},{"issue":"5","key":"2565_CR15","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jbspin.2006.01.025","volume":"73","author":"P Lafforgue","year":"2006","unstructured":"Lafforgue P. Pathophysiology and natural history of avascular necrosis of bone. Joint Bone Spine. 2006;73(5):500\u20137.","journal-title":"Joint Bone Spine"},{"issue":"11","key":"2565_CR16","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00132-018-3649-x","volume":"47","author":"V Krenn","year":"2018","unstructured":"Krenn V, Waldstein W, Najm A, Perino G, Gaulke R. Histopathological classification principles of rheumatic joint diseases: contribution of pathology to the diagnosis. Orthopade. 2018;47(11):939\u201346.","journal-title":"Orthopade"},{"issue":"7","key":"2565_CR17","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/00029330-200604010-00012","volume":"119","author":"L Yin","year":"2006","unstructured":"Yin L, Li YB, Wang YS. Dexamethasone-induced adipogenesis in primary marrow stromal cell cultures: mechanism of steroid-induced osteonecrosis. Chin Med J (Engl). 2006;119(7):581\u20138.","journal-title":"Chin Med J (Engl)"},{"issue":"8","key":"2565_CR18","first-page":"2907","volume":"85","author":"RS Weinstein","year":"2000","unstructured":"Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab. 2000;85(8):2907\u201312.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2565_CR19","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.jcyt.2016.06.005","volume":"18","author":"G Ciapetti","year":"2016","unstructured":"Ciapetti G, Granchi D, Fotia C, Savarino L, Dallari D, Del Piccolo N, et al. Effects of hypoxia on osteogenic differentiation of mesenchymal stromal cells used as a cell therapy for avascular necrosis of the femoral head. Cytotherapy. 2016;18(9):1087\u201399.","journal-title":"Cytotherapy"},{"issue":"3","key":"2565_CR20","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/rheumatology\/kel302","volume":"46","author":"KM Huffman","year":"2007","unstructured":"Huffman KM, Bowers JR, Dailiana Z, Huebner JL, Urbaniak JR, Kraus VB. Synovial fluid metabolites in osteonecrosis. Rheumatology (Oxford). 2007;46(3):523\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"2565_CR21","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.bone.2009.03.665","volume":"45","author":"HK Kim","year":"2009","unstructured":"Kim HK, Bian H, Aya-ay J, Garces A, Morgan EF, Gilbert SR. Hypoxia and HIF-1alpha expression in the epiphyseal cartilage following ischemic injury to the immature femoral head. Bone. 2009;45(2):280\u20138.","journal-title":"Bone"},{"issue":"3","key":"2565_CR22","first-page":"490","volume":"158","author":"C Gillet","year":"2017","unstructured":"Gillet C, Dalla Valle A, Gaspard N, Spruyt D, Vertongen P, Lechanteur J, et al. Osteonecrosis of the femoral head: lipotoxicity exacerbation in MSC and modifications of the bone marrow fluid. Endocrinology. 2017;158(3):490\u2013502.","journal-title":"Endocrinology"},{"issue":"3","key":"2565_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/jb\/mvx076","volume":"163","author":"L Huang","year":"2018","unstructured":"Huang L, Wang Y, Jiang Y, Wu Y, Hu C, Ouyang H. High levels of GSK-3beta signalling reduce osteogenic differentiation of stem cells in osteonecrosis of femoral head. J Biochem. 2018;163(3):243\u201351.","journal-title":"J Biochem"},{"issue":"5","key":"2565_CR24","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/alcalc\/agg106","volume":"38","author":"YC Chao","year":"2003","unstructured":"Chao YC, Wang SJ, Chu HC, Chang WK, Hsieh TY. Investigation of alcohol metabolizing enzyme genes in Chinese alcoholics with avascular necrosis of hip joint, pancreatitis and cirrhosis of the liver. Alcohol Alcohol. 2003;38(5):431\u20136.","journal-title":"Alcohol Alcohol"},{"issue":"12","key":"2565_CR25","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.3899\/jrheum.080416","volume":"35","author":"G Motomura","year":"2008","unstructured":"Motomura G, Yamamoto T, Miyanishi K, Kondo K, Hirota Y, Iwamoto Y. Risk factors for developing osteonecrosis after prophylaxis in steroid-treated rabbits. J Rheumatol. 2008;35(12):2391\u20134.","journal-title":"J Rheumatol"},{"issue":"2","key":"2565_CR26","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3892\/etm.2016.3991","volume":"13","author":"T Wang","year":"2017","unstructured":"Wang T, Teng S, Zhang Y, Wang F, Ding H, Guo L. Role of mesenchymal stem cells on differentiation in steroid-induced avascular necrosis of the femoral head. Exp Ther Med. 2017;13(2):669\u201375.","journal-title":"Exp Ther Med"},{"issue":"5","key":"2565_CR27","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nri3209","volume":"12","author":"K Le Blanc","year":"2012","unstructured":"Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol. 2012;12(5):383\u201396.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2565_CR28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1089\/ten.teb.2011.0488","volume":"18","author":"J Doorn","year":"2012","unstructured":"Doorn J, Moll G, Le Blanc K, van Blitterswijk C, de Boer J. Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements. Tissue Eng Part B Rev. 2012;18(2):101\u201315.","journal-title":"Tissue Eng Part B Rev"},{"issue":"2","key":"2565_CR29","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/00007890-196803000-00009","volume":"6","author":"AJ Friedenstein","year":"1968","unstructured":"Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968;6(2):230\u201347.","journal-title":"Transplantation."},{"issue":"4","key":"2565_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315\u20137.","journal-title":"Cytotherapy."},{"issue":"1\u20132","key":"2565_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diff.2012.08.004","volume":"85","author":"VB Fernandez Vallone","year":"2013","unstructured":"Fernandez Vallone VB, Romaniuk MA, Choi H, Labovsky V, Otaegui J, Chasseing NA. Mesenchymal stem cells and their use in therapy: what has been achieved? Differentiation. 2013;85(1\u20132):1\u201310.","journal-title":"Differentiation"},{"key":"2565_CR32","doi-asserted-by":"publisher","first-page":"185943","DOI":"10.1155\/2012\/185943","volume":"2012","author":"S Kuci","year":"2012","unstructured":"Kuci S, Henschler R, Muller I, Biagi E, Meisel R. Basic biology and clinical application of multipotent mesenchymal stromal cells: from bench to bedside. Stem Cells Int. 2012;2012:185943.","journal-title":"Stem Cells Int"},{"issue":"8","key":"2565_CR33","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3324\/haematol.2015.140368","volume":"101","author":"Z Kuci","year":"2016","unstructured":"Kuci Z, Bonig H, Kreyenberg H, Bunos M, Jauch A, Janssen JW, et al. Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey. Haematologica. 2016;101(8):985\u201394.","journal-title":"Haematologica"},{"issue":"9624","key":"2565_CR34","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","volume":"371","author":"K Le Blanc","year":"2008","unstructured":"Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371(9624):1579\u201386.","journal-title":"Lancet"},{"issue":"1","key":"2565_CR35","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.bone.2011.11.002","volume":"50","author":"D Zhao","year":"2012","unstructured":"Zhao D, Cui D, Wang B, Tian F, Guo L, Yang L, et al. Treatment of early stage osteonecrosis of the femoral head with autologous implantation of bone marrow-derived and cultured mesenchymal stem cells. Bone. 2012;50(1):325\u201330.","journal-title":"Bone"},{"issue":"10","key":"2565_CR36","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1161\/CIRCRESAHA.117.310712","volume":"121","author":"J Bartolucci","year":"2017","unstructured":"Bartolucci J, Verdugo FJ, Gonzalez PL, Larrea RE, Abarzua E, Goset C, et al. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1\/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]). Circ Res. 2017;121(10):1192\u2013204.","journal-title":"Circ Res"},{"key":"2565_CR37","doi-asserted-by":"crossref","unstructured":"Bader P, Kuci Z, Bakhtiar S, Basu O, Bug G, Dennis M, et al. Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). Bone Marrow Transplant. 2018.","DOI":"10.1038\/s41409-018-0102-z"},{"issue":"4","key":"2565_CR38","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/bmt.2016.317","volume":"52","author":"U Salmenniemi","year":"2017","unstructured":"Salmenniemi U, Itala-Remes M, Nystedt J, Putkonen M, Niittyvuopio R, Vettenranta K, et al. Good responses but high TRM in adult patients after MSC therapy for GvHD. Bone Marrow Transplant. 2017;52(4):606\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2565_CR39","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/bmt.2017.35","volume":"52","author":"GM Dotoli","year":"2017","unstructured":"Dotoli GM, De Santis GC, Orellana MD, de Lima PK, Caruso SR, Fernandes TR, et al. Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III\/IV after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017;52(6):859\u201362.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2565_CR40","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/stem.2224","volume":"34","author":"F von Dalowski","year":"2016","unstructured":"von Dalowski F, Kramer M, Wermke M, Wehner R, Rollig C, Alakel N, et al. Mesenchymal stromal cells for treatment of acute steroid-refractory graft versus host disease: clinical responses and long-term outcome. Stem Cells. 2016;34(2):357\u201366.","journal-title":"Stem Cells"},{"issue":"2","key":"2565_CR41","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.bbmt.2013.11.001","volume":"20","author":"J Kurtzberg","year":"2014","unstructured":"Kurtzberg J, Prockop S, Teira P, Bittencourt H, Lewis V, Chan KW, et al. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Biol Blood Marrow Transplant. 2014;20(2):229\u201335.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2565_CR42","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.bbmt.2013.11.033","volume":"20","author":"M Introna","year":"2014","unstructured":"Introna M, Lucchini G, Dander E, Galimberti S, Rovelli A, Balduzzi A, et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transplant. 2014;20(3):375\u201381.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2565_CR43","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/bjh.12545","volume":"163","author":"LM Ball","year":"2013","unstructured":"Ball LM, Bernardo ME, Roelofs H, van Tol MJ, Contoli B, Zwaginga JJ, et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Haematol. 2013;163(4):501\u20139.","journal-title":"Br J Haematol"},{"issue":"3","key":"2565_CR44","first-page":"225","volume":"3","author":"IB Resnick","year":"2013","unstructured":"Resnick IB, Barkats C, Shapira MY, Stepensky P, Bloom AI, Shimoni A, et al. Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC). Am J Blood Res. 2013;3(3):225\u201338.","journal-title":"Am J Blood Res"},{"key":"2565_CR45","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/cells8121577","volume":"8","author":"H Bonig","year":"2019","unstructured":"Bonig H, Kuci Z, Kuci S, Bakhtiar S, Basu O, Bug G, et al. Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation \u201cMSC-FFM\u201d-Outcome Report of 92 Patients. Cells. 2019;8:12.","journal-title":"Cells."},{"issue":"1","key":"2565_CR46","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2334\/josnusd.17-0315","volume":"61","author":"T Abe","year":"2018","unstructured":"Abe T, Sumi K, Kunimatsu R, Oki N, Tsuka Y, Nakajima K, et al. The effect of mesenchymal stem cells on osteoclast precursor cell differentiation. J Oral Sci. 2018;61(1):30\u20135.","journal-title":"J Oral Sci."},{"issue":"13","key":"2565_CR47","doi-asserted-by":"publisher","first-page":"8932","DOI":"10.1073\/pnas.132252399","volume":"99","author":"EM Horwitz","year":"2002","unstructured":"Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA. 2002;99(13):8932\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"2565_CR48","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1097\/01.TP.0000159029.48678.93","volume":"79","author":"K Le Blanc","year":"2005","unstructured":"Le Blanc K, Gotherstrom C, Ringden O, Hassan M, McMahon R, Horwitz E, et al. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation. 2005;79(11):1607\u201314.","journal-title":"Transplantation"},{"issue":"5","key":"2565_CR49","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.3892\/mmr.2016.5745","volume":"14","author":"C Chen","year":"2016","unstructured":"Chen C, Qu Z, Yin X, Shang C, Ao Q, Gu Y, et al. Efficacy of umbilical cord-derived mesenchymal stem cell-based therapy for osteonecrosis of the femoral head: a three-year follow-up study. Mol Med Rep. 2016;14(5):4209\u201315.","journal-title":"Mol Med Rep"},{"issue":"4","key":"2565_CR50","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.3349\/ymj.2016.57.4.1006","volume":"57","author":"Q Fu","year":"2016","unstructured":"Fu Q, Tang NN, Zhang Q, Liu Y, Peng JC, Fang N, et al. Preclinical study of cell therapy for osteonecrosis of the femoral head with allogenic peripheral blood-derived mesenchymal stem cells. Yonsei Med J. 2016;57(4):1006\u201315.","journal-title":"Yonsei Med J"},{"key":"2565_CR51","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.actbio.2016.06.022","volume":"42","author":"N Kaibuchi","year":"2016","unstructured":"Kaibuchi N, Iwata T, Yamato M, Okano T, Ando T. Multipotent mesenchymal stromal cell sheet therapy for bisphosphonate-related osteonecrosis of the jaw in a rat model. Acta Biomater. 2016;42:400\u201310.","journal-title":"Acta Biomater"},{"issue":"1","key":"2565_CR52","doi-asserted-by":"publisher","first-page":"6162","DOI":"10.4081\/or.2016.6162","volume":"8","author":"W Pepke","year":"2016","unstructured":"Pepke W, Kasten P, Beckmann NA, Janicki P, Egermann M. Core decompression and autologous bone marrow concentrate for treatment of femoral head osteonecrosis: a randomized prospective study. Orthop Rev (Pavia). 2016;8(1):6162.","journal-title":"Orthop Rev (Pavia)"},{"issue":"3","key":"2565_CR53","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3325\/cmj.2013.54.219","volume":"54","author":"JR Martin","year":"2013","unstructured":"Martin JR, Houdek MT, Sierra RJ. Use of concentrated bone marrow aspirate and platelet rich plasma during minimally invasive decompression of the femoral head in the treatment of osteonecrosis. Croat Med J. 2013;54(3):219\u201324.","journal-title":"Croat Med J"},{"issue":"1","key":"2565_CR54","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4103\/0019-5413.45322","volume":"43","author":"P Hernigou","year":"2009","unstructured":"Hernigou P, Poignard A, Zilber S, Rouard H. Cell therapy of hip osteonecrosis with autologous bone marrow grafting. Indian J Orthop. 2009;43(1):40\u20135.","journal-title":"Indian J Orthop"},{"issue":"5","key":"2565_CR55","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.bone.2011.07.032","volume":"49","author":"V Gangji","year":"2011","unstructured":"Gangji V, De Maertelaer V, Hauzeur JP. Autologous bone marrow cell implantation in the treatment of non-traumatic osteonecrosis of the femoral head: five year follow-up of a prospective controlled study. Bone. 2011;49(5):1005\u20139.","journal-title":"Bone"},{"issue":"5","key":"2565_CR56","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.arth.2011.08.008","volume":"27","author":"RK Sen","year":"2012","unstructured":"Sen RK, Tripathy SK, Aggarwal S, Marwaha N, Sharma RR, Khandelwal N. Early results of core decompression and autologous bone marrow mononuclear cells instillation in femoral head osteonecrosis: a randomized control study. J Arthroplasty. 2012;27(5):679\u201386.","journal-title":"J Arthroplasty"},{"key":"2565_CR57","doi-asserted-by":"publisher","first-page":"165","DOI":"10.22203\/eCM.v035a12","volume":"35","author":"D Henrich","year":"2018","unstructured":"Henrich D, Seebach C, Verboket R, Schaible A, Marzi I, Bonig H. The osteo-inductive activity of bone-marrow-derived mononuclear cells resides within the CD14+ population and is independent of the CD34+ population. Eur Cell Mater. 2018;35:165\u201377.","journal-title":"Eur Cell Mater"},{"key":"2565_CR58","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13287-015-0105-2","volume":"6","author":"GC Daltro","year":"2015","unstructured":"Daltro GC, Fortuna V, de Souza ES, Salles MM, Carreira AC, Meyer R, et al. Efficacy of autologous stem cell-based therapy for osteonecrosis of the femoral head in sickle cell disease: a five-year follow-up study. Stem Cell Res Ther. 2015;6:110.","journal-title":"Stem Cell Res Ther"},{"issue":"8","key":"2565_CR59","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s00264-012-1525-6","volume":"36","author":"R Civinini","year":"2012","unstructured":"Civinini R, De Biase P, Carulli C, Matassi F, Nistri L, Capanna R, et al. The use of an injectable calcium sulphate\/calcium phosphate bioceramic in the treatment of osteonecrosis of the femoral head. Int Orthop. 2012;36(8):1583\u20138.","journal-title":"Int Orthop"},{"issue":"1","key":"2565_CR60","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.bone.2009.09.001","volume":"46","author":"Y Feng","year":"2010","unstructured":"Feng Y, Yang SH, Xiao BJ, Xu WH, Ye SN, Xia T, et al. Decreased in the number and function of circulation endothelial progenitor cells in patients with avascular necrosis of the femoral head. Bone. 2010;46(1):32\u201340.","journal-title":"Bone"},{"issue":"3","key":"2565_CR61","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jcyt.2018.01.009","volume":"20","author":"K Le Blanc","year":"2018","unstructured":"Le Blanc K, Davies LC. MSCs-cells with many sides. Cytotherapy. 2018;20(3):273\u20138.","journal-title":"Cytotherapy"},{"issue":"3","key":"2565_CR62","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/nrendo.2014.234","volume":"11","author":"WL Grayson","year":"2015","unstructured":"Grayson WL, Bunnell BA, Martin E, Frazier T, Hung BP, Gimble JM. Stromal cells and stem cells in clinical bone regeneration. Nat Rev Endocrinol. 2015;11(3):140\u201350.","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"2565_CR63","first-page":"14528","volume":"8","author":"H Song","year":"2015","unstructured":"Song H, Tao L, Wang F, Wang W, Wei Y, Shen W, et al. Effect of bone mesenchymal stem cells transplantation on the micro-environment of early osteonecrosis of the femoral head. Int J Clin Exp Pathol. 2015;8(11):14528\u201334.","journal-title":"Int J Clin Exp Pathol"},{"key":"2565_CR64","first-page":"139","volume":"69","author":"P Hernigou","year":"2020","unstructured":"Hernigou P. Cellular therapy for the treatment of osteonecrosis: from bench to bedside. Instr Course Lect. 2020;69:139\u201348.","journal-title":"Instr Course Lect"},{"issue":"8","key":"2565_CR65","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1016\/j.arth.2017.02.075","volume":"32","author":"NS Piuzzi","year":"2017","unstructured":"Piuzzi NS, Chahla J, Jiandong H, Chughtai M, LaPrade RF, Mont MA, et al. Analysis of cell therapies used in clinical trials for the treatment of osteonecrosis of the femoral head: a systematic review of the literature. J Arthroplasty. 2017;32(8):2612\u20138.","journal-title":"J Arthroplasty"},{"key":"2565_CR66","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/1471-2474-15-156","volume":"15","author":"RL Lau","year":"2014","unstructured":"Lau RL, Perruccio AV, Evans HM, Mahomed SR, Mahomed NN, Gandhi R. Stem cell therapy for the treatment of early stage avascular necrosis of the femoral head: a systematic review. BMC Musculoskelet Disord. 2014;15:156.","journal-title":"BMC Musculoskelet Disord"},{"key":"2565_CR67","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ijsu.2019.06.016","volume":"69","author":"Z Wang","year":"2019","unstructured":"Wang Z, Sun QM, Zhang FQ, Zhang QL, Wang LG, Wang WJ. Core decompression combined with autologous bone marrow stem cells versus core decompression alone for patients with osteonecrosis of the femoral head: a meta-analysis. Int J Surg. 2019;69:23\u201331.","journal-title":"Int J Surg"},{"key":"2565_CR68","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/ijms19092526","volume":"19","author":"AE Rapp","year":"2018","unstructured":"Rapp AE, Bindl R, Erbacher A, Kruchen A, Rojewski M, Schrezenmeier H, et al. Autologous mesenchymal stroma cells are superior to allogeneic ones in bone defect regeneration. Int J Mol Sci. 2018;19:9.","journal-title":"Int J Mol Sci."},{"issue":"8","key":"2565_CR69","doi-asserted-by":"publisher","first-page":"7874","DOI":"10.1016\/j.actbio.2013.04.035","volume":"9","author":"A Berner","year":"2013","unstructured":"Berner A, Reichert JC, Woodruff MA, Saifzadeh S, Morris AJ, Epari DR, et al. Autologous vs allogenic mesenchymal progenitor cells for the reconstruction of critical sized segmental tibial bone defects in aged sheep. Acta Biomater. 2013;9(8):7874\u201384.","journal-title":"Acta Biomater."},{"issue":"4","key":"2565_CR70","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.arth.2015.08.017","volume":"31","author":"MT Houdek","year":"2016","unstructured":"Houdek MT, Wyles CC, Packard BD, Terzic A, Behfar A, Sierra RJ. Decreased osteogenic activity of mesenchymal stem cells in patients with corticosteroid-induced osteonecrosis of the femoral head. J Arthroplasty. 2016;31(4):893\u20138.","journal-title":"J Arthroplasty"},{"issue":"8","key":"2565_CR71","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jcyt.2019.06.002","volume":"21","author":"D Granchi","year":"2019","unstructured":"Granchi D, Ciapetti G, Gomez-Barrena E, Rojewski M, Rosset P, Layrolle P, et al. Biomarkers of bone healing induced by a regenerative approach based on expanded bone marrow-derived mesenchymal stromal cells. Cytotherapy. 2019;21(8):870\u201385.","journal-title":"Cytotherapy"},{"key":"2565_CR72","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/1479-5876-12-114","volume":"12","author":"Q Wen","year":"2014","unstructured":"Wen Q, Zhou C, Luo W, Zhou M, Ma L. Pro-osteogenic effects of fibrin glue in treatment of avascular necrosis of the femoral head in vivo by hepatocyte growth factor-transgenic mesenchymal stem cells. J Transl Med. 2014;12:114.","journal-title":"J Transl Med"},{"issue":"2","key":"2565_CR73","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1159\/000491906","volume":"48","author":"F Zhang","year":"2018","unstructured":"Zhang F, Peng WX, Wang L, Zhang J, Dong WT, Wu JH, et al. Role of FGF-2 transfected bone marrow mesenchymal stem cells in engineered bone tissue for repair of avascular necrosis of femoral head in rabbits. Cell Physiol Biochem. 2018;48(2):773\u201384.","journal-title":"Cell Physiol Biochem"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02565-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-020-02565-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02565-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T23:37:27Z","timestamp":1634686647000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-020-02565-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,20]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2565"],"URL":"https:\/\/doi.org\/10.1186\/s12967-020-02565-9","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,20]]},"assertion":[{"value":"18 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"B.H., and B.P. are co-owners of IP for an MSC preparation for which they have received royalties and licensing fees. E.S. declares to have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"399"}}